SAN DIEGO, March 12, 2024 /PRNewswire/ Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today.
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses
Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney.
SAN DIEGO, Jan. 2, 2024 /PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of our third and final randomized placebo-controlled cohort in the Phase 1b MAD study is an exciting step for